Skip to content

Listen Now

Threat Status podcast: Is the Biden administration sabotaging Trump on Ukraine policy?

Advertisement

In this undated photo provided by Dendreon Corp., an employee works on the company's prostate cancer drug Provenge at a plant in Morris Plains, N.J. Medicare officials said Wednesday, March 30, 2011 that the program will pay the $93,000 cost of the drug, an innovative therapy that typically gives men suffering from the disease an extra four months to live. (AP Photo/Dendreon Corp.) NO SALES

In this undated photo provided by Dendreon Corp., an employee works on the company's prostate cancer drug Provenge at a plant in Morris Plains, N.J. Medicare officials said Wednesday, March 30, 2011 that the program will pay the $93,000 cost of the drug, an innovative therapy that typically gives men suffering from the disease an extra four months to live. (AP Photo/Dendreon Corp.) NO SALES

Featured Photo Galleries